160 related articles for article (PubMed ID: 17666440)
1. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
[TBL] [Abstract][Full Text] [Related]
3. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
4. Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
Pocock JM; Vasconcelos JC; Ostör AJ
Rheumatology (Oxford); 2008 Jul; 47(7):1073-6. PubMed ID: 18503089
[TBL] [Abstract][Full Text] [Related]
5. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
6. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis.
Greenwood MC; Rathi J; Hakim AJ; Scott DL; Doyle DV
Rheumatology (Oxford); 2007 Jul; 46(7):1165-7. PubMed ID: 17488751
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
[TBL] [Abstract][Full Text] [Related]
8. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice.
Smith N; Ding T; Butt S; Gadsby K; Deighton C
Rheumatology (Oxford); 2008 Sep; 47(9):1389-91. PubMed ID: 18603597
[TBL] [Abstract][Full Text] [Related]
9. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic.
Hider SL; Tanveer W; Brownfield A; Mattey DL; Packham JC
Rheumatology (Oxford); 2009 Sep; 48(9):1152-4. PubMed ID: 19608723
[TBL] [Abstract][Full Text] [Related]
10. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
[TBL] [Abstract][Full Text] [Related]
12. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
13. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
14. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
Soubrier M; Zerkak D; Gossec L; Ayral X; Roux C; Dougados M
J Rheumatol; 2006 Jul; 33(7):1243-6. PubMed ID: 16622906
[TBL] [Abstract][Full Text] [Related]
15. The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy.
Bingham SJ; Buch MH; Tennant A; Emery P
Rheumatology (Oxford); 2004 Mar; 43(3):364-8. PubMed ID: 14657509
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
17. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis.
Radovits BJ; Fransen J; Eijsbouts A; van Riel PL; Laan RF
Rheumatology (Oxford); 2009 Aug; 48(8):906-10. PubMed ID: 19478038
[TBL] [Abstract][Full Text] [Related]
18. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
[TBL] [Abstract][Full Text] [Related]
19. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers.
Abhishek A; Butt S; Gadsby K; Zhang W; Deighton CM
J Clin Rheumatol; 2010 Jan; 16(1):15-8. PubMed ID: 20051749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]